NR3C2 and hydrops fetalis: In the FINEARTS-HF trial, the nonsteroidal mineralocorticoid receptor antagonist finerenone was similarly effective in reducing the primary outcome of total worsening HF events, including HF hospitalizations or urgent HF visits, and cardiovascular death, across all age categories.